SCHEMBL752748

SCHEMBL752748

CCOc1ccc(C(N)CS(C)(=O)=O)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 11/20 0.53
PDE4A P27815 6/20 0.53
PDE4C Q08493 6/20 0.53
PDE4D Q08499 6/20 0.53
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPK1 P28482 1/20 0.47
TSHR P16473 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15580926 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL302947 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL636037 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL15869339 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL15869362 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL15580915 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL29679711 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL753579 0.94 PDE4B (0.59) PDE4BPDE4APDE4CPDE4D
SCHEMBL751651 0.90 CA1 (0.51) PDE4BPDE4APDE4CPDE4DMAPK1
SCHEMBL706429 0.85 PDE4B (0.50) PDE4BPDE4APDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107964016-B Thiophene derivatives 天津合美医药科技有限公司 2021-10-01 CN disclosed
CN-108059635-B Thiophene derivatives 天津合美医药科技有限公司 2021-10-01 CN disclosed
CN-107722036-B Thiophene derivatives 天津合美医药科技有限公司 2020-09-04 CN disclosed
US-10611775-B2 Thiophene derivatives TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2020-04-07 US disclosed
US-20190322684-A1 THIOPHENE DERIVATIVES TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2019-10-24 US disclosed
US-10385062-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2019-08-20 US disclosed
US-20170197982-A1 THIOPHENE DERIVATIVES GANZHOU HEMAY PHARMACEUTICAL CO., LTD. (CN) 2017-07-13 US disclosed
US-9630975-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-04-25 US disclosed
US-8952178-B2 Thiophene derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-02-10 US disclosed
US-20140255342-A1 THIOPHENE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-09-11 US disclosed
EP-2431371-B1 THIOPHENE DERIVATIVES TIANJIN HEMAY BIO TECH CO LTD (CN) 2013-10-09 EP disclosed
US-20120107269-A1 THIOPHENE DERIVATIVES Tianjin Hemay Biotech Co., Ltd (CN) 2012-05-03 US disclosed
EP-2431371-A1 THIOPHENE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2012-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385062-B2 Thiophene derivatives TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-20120107269-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-10611775-B2 Thiophene derivatives TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-20170197982-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-20140255342-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885
US-20190322684-A1 THIOPHENE DERIVATIVES TSHR, RB1, TAS2R7 PDE4B 1282/4885PDE4A 1596/4885PDE4C 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.